Loading...
Beactica Initiates Drug Discovery Collaboration with Medivir
11-Jun-2014
- Sweden
Advertisement
Beactica, announced that it has entered into an agreement with Medivir AB. Under the agreement, Beactica will use its proprietary discovery platform to identify novel hits against a disease-relevant protease of therapeutic interest to Medivir. Financial terms of the agreement were not disclosed.
“We are pleased that Medivir has selected Beactica to advance one of their prioritized discovery programmes”, said Beactica CEO, Dr Per Källblad. “Medivir is at a very exciting point in their development and we are looking forward to tackle this challenging project together with their team of innovative scientists”.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
„EXIST Women“: new funding for female founders - Women have been severely underrepresented in the start-up ecosystem for decades
Bioniche Reaches Special Protocol Assessment Agreement with U.S. FDA for Phase III Comparative Bladder Cancer Trial
CRISPR editing reduces repetitive behavior in mice with a form of autism
Queen's study aims to use stem cells to help save sight of diabetes sufferers
LEGO toy helps researchers learn what happens on nanoscale
Study reveals key structure in telomerase enzyme, a target for cancer drugs
Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin Therapeutics
Organon and Dyax enter into therapeutic antibody alliance
University of Nottingham and BioFocus sign compound management agreement
Neurimmune Therapeutics Announces Advancement of Alzheimer’s Program into Preclinical Development
YM BioSciences reports Nimotuzumab approved for marketing in Mexico - YM enrolls first patients in multinational randomized, double-blind brain metastases trial
